Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name - Seite 2
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should,"
"might," "potential," or "continue" and variations or similar expressions, including statements related to: the company's belief that sPLA2 inhibitors could provide a powerful anti-inflammatory
effect since they act at the inception of inflammatory cascades rather than after inflammation has occurred; the company's belief that daniluromer represents a potentially powerful new way to
manage inflammation without the safety concerns and side effects of topical corticosteroids, especially for patients with chronic inflammation; the company's expectation that the name daniluromer
will be published in an upcoming WHO list of recommended international nonproprietary names; and the company's timing and plans regarding its clinical studies in general. Readers should not unduly
rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such
forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.
Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's
operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested
in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business,
Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as Covid-19.
Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business,
please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of
the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.